Stockreport

BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

BriaCell Therapeutics Corp. - Common Shares  (BCTX) 
PDF Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study Disease control rate of 50% in e [Read more]